NASDAQ:CPIX - Cumberland Pharmaceuticals Stock Price, Forecast & News

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) released its quarterly earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.11 by $0.10. The specialty pharmaceutical company earned $10.37 million during the quarter, compared to analyst estimates of $12.65 million. Cumberland Pharmaceuticals had a negative net margin of 10.13% and a positive return on equity of 6.76%. View Cumberland Pharmaceuticals' Earnings History.

Cumberland Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cumberland Pharmaceuticals.

1 brokerages have issued twelve-month price targets for Cumberland Pharmaceuticals' shares. Their forecasts range from $9.75 to $9.75. On average, they anticipate Cumberland Pharmaceuticals' stock price to reach $9.75 in the next twelve months. This suggests a possible upside of 121.6% from the stock's current price. View Analyst Price Targets for Cumberland Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cumberland Pharmaceuticals.

Media headlines about CPIX stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cumberland Pharmaceuticals earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Cumberland Pharmaceuticals.

Cumberland Pharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 82,400 shares, a decline of 12.7% from the December 31st total of 94,400 shares. Based on an average trading volume of 14,900 shares, the short-interest ratio is currently 5.5 days. Currently, 0.9% of the shares of the stock are sold short. View Cumberland Pharmaceuticals' Current Options Chain.

Some companies that are related to Cumberland Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Protalix Biotherapeutics (PLX), AcelRx Pharmaceuticals (ACRX), Akari Therapeutics (AKTX), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Catalyst Biosciences (CBIO), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Dicerna Pharmaceuticals (DRNA).

Cumberland Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Ariel Investments LLC (6.65%) and Acadian Asset Management LLC (0.65%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, Caroline Young, Gordon R Bernard, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View Institutional Ownership Trends for Cumberland Pharmaceuticals.

CPIX stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Cumberland Pharmaceuticals.

CPIX stock was purchased by a variety of institutional investors in the last quarter, including Ariel Investments LLC. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joey A Jacobs, Joseph C Galante, Kenneth Krogulski and Michael Bonner. View Insider Buying and Selling for Cumberland Pharmaceuticals.

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CPIX stock can currently be purchased for approximately $4.40.

Cumberland Pharmaceuticals has a market capitalization of $66.79 million and generates $40.74 million in revenue each year. The specialty pharmaceutical company earns $-6,960,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. Cumberland Pharmaceuticals employs 80 workers across the globe.View Additional Information About Cumberland Pharmaceuticals.

The official website for Cumberland Pharmaceuticals is http://www.cumberlandpharma.com/.

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected]